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from the 
The immunosuppressive effects of FR 900506 
were investigated for one month after 
canine kidney and liver transplantation. 
Eight untreated kidney recipients lived for 
8 to 19 days, mean 12.1. In contrast, the 
one month survival of dogs given FR 900506 
in daily oral doses of 0.5, 1.0, and 1.5 
mg/kg was 2/6, 3/6, and 4/6 respectively. 
The one month survival of liver recipients 
was 4/5 compared to one month survival of 
1/8 in historical untreated controls. 
There was no evidence from biochemical 
tests of hepatotoxicity or nephrotoxicity. 
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FR 90 0 5 06 ( FR ) i san ew i rrnnu nos u p pre s s i ve ag e n t 
produced by Streptomyces tsukubaensis. It inhibits 
I ymp hoc Y t e pro I i fer a t ion i n in Yili:.Q. s y stem sse v era I 
hundred times more effectively than cyclosporine (CyA), 
(1,2) and greatly prolongs the survival of heterotopic 
heart grafts in rats (1,3). In this study, the effect 
of FR on canine kidney and liver grafts was determined 
for the first postoperative month. 
Fasted beagle and mongrel dogs, weighing 13-15kg, were 
submitted to intraabdominal kidney transplantation and 
bilateral nephrectomy (4) or to orthotopic liver 
transplantation during veno-venous bypass (5). Beagle 
to beagle (B/B) or mongrel to beagle (M/B) strain 
combinations were used. 
FR was supplied as a powder by the Fujisawa 
Pharmac eu tic a I Company, Inc., Osaka, Japan. The ag en t 
was placed into corrnnercial capsules and given orally to 
the animals each morning, starting on the morning after 
transplantation. The kidney transplantation groups 
were as follows: 
Group I : no treatment (N=8, 6B/B and 2 M/B) 
Group I I : O.5mg/kg/day (N=6, 6 M/B) 
Group II I : 1.0mg/kg/day (N=6, 6 M/B) 
Group I V: 1.5mg/kg/day (N=6, 6 M/B) 
For the 5 live r transplantations, the B/B strain 
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comb i na t i on was used. The oral FR dose was 
1.0mg/kg/day. The antibiotic cephalosporin was given 
in a one gram dose on the morning of transplantation 
and intramuscularly (one gram) for 3 days after the 
operation. Because FR causes vomiting in dogs, 2 mg 
atropine sulphate were given I.M. twice a day for the 
first postoperative week, and once a day for the second 
week. During the third week, their daily atropine dose 
was reduced to one mg. 
Blood 
determination 
samples 
of blood 
were drawn every 
urea nitrogen 
3 days for 
(BUN) , s e r urn 
creatinine, serum glutamic oxaloacetic transaminase 
(SGOT), and total bilirubin. Animals that died were 
autopsied immediately wi th one exception. 
Histopathological studies will be reported elsewhere. 
Of the 27 recipients, one animal died at day 6 from 
intussusception and was excluded from survival 
analyses. All of the treated animals had vomiting and 
em a cia t ion d uri n g the fir s tan d sec 0 n d po s top era t i ve 
weeks, but this improved gradually thereafter in most 
of the animals. 
Su.tl!il!W: FR had a dose dependent effect on 
survival (Figure 1). One month survival was 0% ( 0/8) 
in Group I , 33% (2/6) in Group I I , 50% (3/6) in Group 
I II , and 67% ( 4/6) in Group I V • All of the deaths in 
Group I followed severe rejection. Deaths in Group II 
were caused by rejection (day 13 and 28), 
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intussusception (day 24), and unknown causes (no 
autopsy, day 16). Deaths in Group III were from 
rejection (day 16) and lethal emaciation (days 14 and 
21). Deaths in Group IV were from unknown cause (day 
17) and possible pancreatitis (day 28). 
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FIGURE 1 One month survival of Group I (untreated 
control), Group II (O.5mg/kg/day), Group III 
(1.0mg/kg/day) and Group IV (1.5mg/kg/day) 
after kidney transplantation • 
.lkn.E!l and Hepatic Functions Changes in serum 
creatinine are shown in Figure 2. FR showed dose-
dependent protection of renal function, with the best 
results in animals treated with 1.5mg/kg/day. There 
were no abnormalities in SGOT and bilirubin. 
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FIGURE 2 Changes in serum creatinine of Group I 
(untreated control), Group II (O.5mg/kg/day), 
Group I I I (1. Omg/kg/day) and Group IV 
(1.5mg/kg/day) after kidney transplantation. 
SuryiYal: Ten liver transplantation were performed using 
B/B combinations. Only the 5 animals which survived 
more than 5 days were used for statistical analysis; 
the other 5 died perioperatively of technical 
compl ications. One of the defini tive dogs died of 
b iIi a r y per ito n i ti s 1 0 day s aft e r the 0 per a t ion. Th e 
other 4 are still alive after more than 30 days. 
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(Figure 3). 
bil irubin. 
There was never an elevation of total 
The creatinine and BUN were normal except 
in the dog which died of peritonitis (Figure 3) 
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FIGURE 3 Changes in SGOT, total bilirubin, BUN and 
creatinine of animals after liver 
transplantaion. 
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DISWSSI(ll 
This study in dogs has confirmed that FR is a potent 
immunosuppres s i ve agent when given orall y. The low 
dose of O.5mg/kg/day had a demonstrable but weak 
effect. At 1.0mg/kg/day and 1.5mg/kg/day, the results 
became increasingly predictable. 
The side effects of FR were severe with the first 
doses and inc I uded vom it i ng, and emac i at ion bu t these 
lessened in most of the animals after 2-3 weeks. These 
toxic manifestations have not been seen in rats (1,3). 
Intussusception was not commonly observed, possibly 
because of prophylactic treatment with atropine. 
Kidney and liver function tests were not adversely 
effected by FR. Histopathologic studies looking for 
organ specific toxicity are underway. 
After canine liver transplantation, FR gave better 
results than previously achieved with CyA (6). In 
those earlier studies, 7 of 8 untreated animals died 
within 1 months, and the mean survival time was 
11.8+9.6 (S.D.) days. When treated with 20mg/kg/day of 
oral CyA, 3 of 9 animals died within 
result of rejection. Two of the 
treated dogs had persistent elevation 
1 month, 2 as the 
remaining 6 CyA 
of bilirubin at 1 
month and they later died of rejection. In contrast 4 
of the 5 FR treated liver recipients survived more than 
1 month, and none of the 5 had jaundice on late SOOT 
increases. 
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